LFST Earnings Prediction
The chart below shows how LFST performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LFST sees a +0.76% change in stock price 10 days leading up to the earnings, and a -2.53% change 10 days following the report. On the earnings day itself, the stock moves by -0.26%. This data can give you a slight idea of what to expect for the next quarter's release.
LFST Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
312.72M
18.95%
0.13%
Gross Margin
--
--
--
Operating Margin
0.13%
101.29%
-102.76%
Net Margin
-1.90%
-91.89%
-74.50%
EPS
-0.02
-88.24%
-66.67%
No Data Available
LFST Earnings Analysis
LifeStance Health Group, Inc. Common Stock Corporation (LFST.O) Earnings Conference Call
Positive
Revenue Surge: 1. Strong Revenue Growth: LifeStance Health reported a revenue of $313 million for Q3 2024, reflecting a 19% increase year-over-year, driven by higher total revenue per visit and increased visit volumes.
Visit Volume Surge: 2. Increased Visit Volumes: The company achieved 2 million visit volumes in Q3 2024, marking a 15% year-over-year increase, primarily due to the growth in clinician numbers.
Adjusted EBITDA Surge: 3. Significant Adjusted EBITDA Growth: Adjusted EBITDA reached $31 million in Q3 2024, representing a remarkable 110% increase year-over-year, and the fourth consecutive quarter of doubling adjusted EBITDA.
Center Margin Increase: 4. Improved Center Margin: Center margin for the quarter was $100 million, a 32% increase year-over-year, attributed to higher total revenue per visit and operational efficiencies.
Strong Cash Flow Generation: 5. Positive Cash Flow Generation: LifeStance generated solid free cash flow of $18 million in Q3 2024, exiting the quarter with $103 million in cash, indicating strong financial health and liquidity.
Negative
Payer Rate Decrease Impact: 1. Negative Impact from Payer Rate Decrease: The third quarter reflected a decrease in rates from a single outlier payer, which negatively impacted overall revenue despite mitigated effects from negotiated rate increases with other payers.
Payroll Cycle Cash Impact: 2. Cash Flow Impact from Payroll Change: The implementation of a biweekly payroll cycle for clinicians is expected to have a negative cash impact of approximately $15 million in Q4 2024.
Revenue per Visit Decline: 3. Expected Decline in Revenue per Visit: The company anticipates a modest quarter-over-quarter decline in total revenue per visit due to one-time rate favorability experienced in Q3 2024.
Clinician Retention Challenges: 4. Challenges in Clinician Retention: Despite adding 285 net clinicians in Q3, the company acknowledges ongoing challenges in retaining clinicians, indicating that turnover remains a factor in their workforce stability.
Margin Compression Outlook: 5. Projected Margin Compression: For 2025, the company expects minimal margin improvement due to flat total revenue per visit and increasing clinician costs, indicating potential pressure on profitability.
LFST FAQs
How does LFST typically perform around its earnings report dates?
Is LifeStance Health Group, Inc. (LFST) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LFST Earning Call Sentiment
LifeStance Health Group, Inc. (LFST) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
LFST.O
-1.01%Positive
The earnings call highlights strong financial performance with a 19% revenue growth and increased EBITDA. The company raised its guidance across several metrics, indicating confidence in future performance. Despite regulatory and operational challenges, the positive payer engagement and clinician growth efforts are encouraging. The Q&A section reflected a stable recruiting environment and a positive outlook for telehealth reimbursements. Given the raised guidance and strong current metrics, the stock is likely to see a positive movement, potentially benefiting from its small-cap status.
